Skip to main content
Erschienen in: Journal of Community Health 4/2018

06.03.2018 | Original Paper

A Descriptive Analysis of a Community Clinic Providing Hepatitis C Treatment to Poor and Uninsured Patients

verfasst von: Omar T. Sims, Pamela A. Melton, Shaonin Ji

Erschienen in: Journal of Community Health | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

This study describes clinical characteristics of poor and uninsured patients living with hepatitis C virus (HCV) who received care from a multidisciplinary HCV clinic, reports treatment completion and cure rates, and estimates the cost of HCV medications provided at no cost to uninsured patients. A retrospective chart review was performed and identified 69 uninsured HCV patients who received medical care at Mercy Health Center, a small non-profit community clinic, between January 2008 and March 2015. Three-fourths of the patients were unemployed, a third had multiple HCV exposures, nearly half acquired HCV due to illicit drug use, and more than half had active psychiatric disorders. Of those who received HCV treatment, 81% completed treatment and 85% were achieved virological cure. The multidisciplinary community clinic provided > $1.4 million of HCV antivirals at no cost to uninsured patients. Findings suggest a multidisciplinary community clinic comprised of a social worker, pharmacist, gastroenterologist, nurse, nurse practitioner, psychologist, and dietitian can help patients achieve HCV treatment completion and cure rates comparable to traditional physician-led clinics, and successfully manage uninsured and underserved HCV patients—who are often regarded as “difficult-to-treat” patients. Public health social workers and other health professionals are encouraged to advocate for treatment and care of poor and uninsured patients living with HCV in health agencies and health systems, otherwise population-wide reductions in HCV morbidity and mortality will not be realized.
Literatur
2.
Zurück zum Zitat Backus, L. I., Boothroyd, D. B., Phillips, B. R., Belperio, P., Halloran, J., & Mole, L. A. (2011). A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 9(6), 509.e1–516.e1. https://doi.org/10.1016/j.cgh.2011.03.004.CrossRef Backus, L. I., Boothroyd, D. B., Phillips, B. R., Belperio, P., Halloran, J., & Mole, L. A. (2011). A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 9(6), 509.e1–516.e1. https://​doi.​org/​10.​1016/​j.​cgh.​2011.​03.​004.CrossRef
4.
Zurück zum Zitat Ditah, I., Al Bawardy, B., Gonzalez, H. C., Saberi, B., Ditah, C., Kamath, P. S., & Charlton, M. (2015). Lack of health insurance limits the benefits of hepatitis C virus screening: Insights from the National Health and Nutrition Examination Hepatitis C follow-up study. The American Journal of Gastroenterology, 110(8), 1126–1133. https://doi.org/10.1038/ajg.2015.31.CrossRefPubMed Ditah, I., Al Bawardy, B., Gonzalez, H. C., Saberi, B., Ditah, C., Kamath, P. S., & Charlton, M. (2015). Lack of health insurance limits the benefits of hepatitis C virus screening: Insights from the National Health and Nutrition Examination Hepatitis C follow-up study. The American Journal of Gastroenterology, 110(8), 1126–1133. https://​doi.​org/​10.​1038/​ajg.​2015.​31.CrossRefPubMed
8.
Zurück zum Zitat King, A., Bornschlegel, K., Johnson, N., Rude, E., & Laraque, F. (2016). Barriers to treatment among New York City residents with chronic hepatitis C virus infection, 2014. Public Health Reports (Washington, D.C.: 1974), 131(3), 430–437.CrossRef King, A., Bornschlegel, K., Johnson, N., Rude, E., & Laraque, F. (2016). Barriers to treatment among New York City residents with chronic hepatitis C virus infection, 2014. Public Health Reports (Washington, D.C.: 1974), 131(3), 430–437.CrossRef
10.
Zurück zum Zitat Mahajan, R., Xing, J., Liu, S. J., Ly, K. N., Moorman, A. C., Rupp, L., … Chronic Hepatitis Cohort Study (CHeCS) Investigators. (2014). Mortality among persons in care with hepatitis C virus infection: The Chronic Hepatitis Cohort Study (CHeCS), 2006–2010. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 58(8), 1055–1061. https://doi.org/10.1093/cid/ciu077.CrossRef Mahajan, R., Xing, J., Liu, S. J., Ly, K. N., Moorman, A. C., Rupp, L., … Chronic Hepatitis Cohort Study (CHeCS) Investigators. (2014). Mortality among persons in care with hepatitis C virus infection: The Chronic Hepatitis Cohort Study (CHeCS), 2006–2010. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 58(8), 1055–1061. https://​doi.​org/​10.​1093/​cid/​ciu077.CrossRef
16.
Zurück zum Zitat Scaife, J., Kuti, E., Acampa, L., Alvrtsyan, H., Million, R., Miyasato, G., … Kokkotos, F. K. (2013). Uninsured chronic hepatitis C patients and their cost implications under the affordable care act—ClinicalKey. Value in Health, 16(3), A98.CrossRef Scaife, J., Kuti, E., Acampa, L., Alvrtsyan, H., Million, R., Miyasato, G., … Kokkotos, F. K. (2013). Uninsured chronic hepatitis C patients and their cost implications under the affordable care act—ClinicalKey. Value in Health, 16(3), A98.CrossRef
22.
Zurück zum Zitat Trooskin, S. B., Reynolds, H., & Kostman, J. R. (2015). Access to costly new hepatitis C drugs: Medicine, money, and advocacy. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 61(12), 1825–1830. https://doi.org/10.1093/cid/civ677.CrossRef Trooskin, S. B., Reynolds, H., & Kostman, J. R. (2015). Access to costly new hepatitis C drugs: Medicine, money, and advocacy. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 61(12), 1825–1830. https://​doi.​org/​10.​1093/​cid/​civ677.CrossRef
24.
Zurück zum Zitat Yau, A. H. L., & Yoshida, E. M. (2014). Hepatitis C drugs: The end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: A concise review. Canadian Journal of Gastroenterology & Hepatology, 28(8), 445–451.CrossRef Yau, A. H. L., & Yoshida, E. M. (2014). Hepatitis C drugs: The end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: A concise review. Canadian Journal of Gastroenterology & Hepatology, 28(8), 445–451.CrossRef
25.
Zurück zum Zitat Zhang, J., Nguyen, D., & Hu, K.-Q. (2016). Chronic hepatitis C virus infection: A review of current direct-acting antiviral treatment strategies. North American Journal of Medicine & Science, 9(2), 47–54. Zhang, J., Nguyen, D., & Hu, K.-Q. (2016). Chronic hepatitis C virus infection: A review of current direct-acting antiviral treatment strategies. North American Journal of Medicine & Science, 9(2), 47–54.
Metadaten
Titel
A Descriptive Analysis of a Community Clinic Providing Hepatitis C Treatment to Poor and Uninsured Patients
verfasst von
Omar T. Sims
Pamela A. Melton
Shaonin Ji
Publikationsdatum
06.03.2018
Verlag
Springer US
Erschienen in
Journal of Community Health / Ausgabe 4/2018
Print ISSN: 0094-5145
Elektronische ISSN: 1573-3610
DOI
https://doi.org/10.1007/s10900-018-0476-2

Weitere Artikel der Ausgabe 4/2018

Journal of Community Health 4/2018 Zur Ausgabe